FI20115914A0 - MODIFIED ONCOLYTIC VIRUS - Google Patents

MODIFIED ONCOLYTIC VIRUS

Info

Publication number
FI20115914A0
FI20115914A0 FI20115914A FI20115914A FI20115914A0 FI 20115914 A0 FI20115914 A0 FI 20115914A0 FI 20115914 A FI20115914 A FI 20115914A FI 20115914 A FI20115914 A FI 20115914A FI 20115914 A0 FI20115914 A0 FI 20115914A0
Authority
FI
Finland
Prior art keywords
virus vectors
vaccinia
vaccinia virus
modified oncolytic
oncolytic virus
Prior art date
Application number
FI20115914A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI20115914L (en
Inventor
Akseli Hemminki
Sari Pesonen
Marko Ahonen
Markus Vaehae-Koskela
Suvi Parviainen
Vincenzo Cerullo
Iulia Diaconu
Eerika Karli
Original Assignee
Akseli Hemminki
Sari Pesonen
Marko Ahonen
Markus Vaehae-Koskela
Suvi Parviainen
Vincenzo Cerullo
Iulia Diaconu
Eerika Karli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akseli Hemminki, Sari Pesonen, Marko Ahonen, Markus Vaehae-Koskela, Suvi Parviainen, Vincenzo Cerullo, Iulia Diaconu, Eerika Karli filed Critical Akseli Hemminki
Priority to FI20115914A priority Critical patent/FI20115914L/en
Publication of FI20115914A0 publication Critical patent/FI20115914A0/en
Priority to PCT/FI2012/050895 priority patent/WO2013038066A1/en
Publication of FI20115914L publication Critical patent/FI20115914L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Abstract

The invention relates to modified oncolytic vaccinia virus vectors and their uses in cancer therapy. The vaccinia virus vectors comprise inactivating mutations in the thymidine kinase gene and in the vaccinia growth factor gene in addition to genes encoding marker or adjuvant proteins. A production method for the inventive vaccinia construct is also disclosed. The vaccinia virus vectors are useful for systemic and sequential therapeutic use for cancer.
FI20115914A 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS FI20115914L (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20115914A FI20115914L (en) 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS
PCT/FI2012/050895 WO2013038066A1 (en) 2011-09-16 2012-09-14 Modified oncolytic vaccinia virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20115914A FI20115914L (en) 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS

Publications (2)

Publication Number Publication Date
FI20115914A0 true FI20115914A0 (en) 2011-09-16
FI20115914L FI20115914L (en) 2013-03-17

Family

ID=44718819

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115914A FI20115914L (en) 2011-09-16 2011-09-16 MODIFIED ONCOLYTIC VIRUS

Country Status (2)

Country Link
FI (1) FI20115914L (en)
WO (1) WO2013038066A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
WO2015076422A1 (en) 2013-11-21 2015-05-28 国立大学法人鳥取大学 Mitogen-activated protein kinase-dependent recombinant vaccinia virus (md-rvv) and use thereof
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR101845739B1 (en) * 2014-10-08 2018-04-05 부산대학교 산학협력단 Novel Oncolytic Virus, Method for Preparing, and Uses thereof
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (en) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 Use of MVA or MVA delta E3L as an immunotherapeutic agent for solid tumors
KR20160140075A (en) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 Promoter derived from the poxviridae and vector including the same
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
EP3400292B1 (en) 2016-01-08 2020-08-26 Replimune Limited Use of an oncolytic virus for the treatment of cancer
AU2017222687B2 (en) 2016-02-25 2022-02-24 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human Flt3L and use thereof as immuno-therapeutic agents against solid tumors
CN116440176A (en) 2016-02-25 2023-07-18 纪念斯隆凯特琳癌症中心 Replication-competent attenuated vaccinia virus with thymidine kinase deficiency and with or without human FLT3L or GM-CSF expression
CN110022867A (en) 2016-09-21 2019-07-16 斯蒂芬·H·索恩 High mobility group protein BOX I mutant
EP3535389A4 (en) 2016-11-02 2020-06-03 David Evans Synthetic chimeric poxviruses
JP7110203B2 (en) * 2016-12-28 2022-08-01 トランジェーヌ Oncolytic viruses and therapeutic molecules
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
EP3641814A4 (en) 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
KR20200037353A (en) 2017-08-07 2020-04-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 Platform for creating safe cell therapy products
BR112020022181A2 (en) * 2018-05-02 2021-02-09 Tonix Pharma Holdings Limited synthetic chimeric vaccinia virus
EP3849314A4 (en) * 2018-09-14 2021-12-08 Mayo Foundation for Medical Education and Research Materials and methods for treatment with oncolytic viruses and modified car t cells
CN109234238A (en) * 2018-09-30 2019-01-18 杭州华安单抗生物技术有限公司 Cell strain and its preparation method of application, the cultivating system of B cell and cultural method and antibody
WO2020086423A1 (en) * 2018-10-22 2020-04-30 Icell Kealex Therapeutics Mutant vaccinia viruses and use thereof
US20200352993A1 (en) * 2019-05-09 2020-11-12 Sator Therapeutics LLC Delivery of oncolytic viruses using dendritic cells
CN111979204B (en) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 Oncolytic vaccinia virus carrying sponge lectin gene, construction method and application
CA3221664A1 (en) * 2021-06-17 2022-12-22 Stephen Howard Thorne Tnfsf-l fusion proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1754002B (en) * 2002-08-12 2010-09-08 杰能斯有限公司 Compositions concerning poxviruses and cancer and its preparation method
WO2008043576A1 (en) * 2006-10-13 2008-04-17 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer

Also Published As

Publication number Publication date
FI20115914L (en) 2013-03-17
WO2013038066A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
FI20115914A0 (en) MODIFIED ONCOLYTIC VIRUS
CY1119960T1 (en) METHODS TO INCREASE THE EFFECTIVENESS OF FOLR1 CANCER TREATMENT
SA518400424B1 (en) Antibody molecules for cancer treatment
AU2017261625B2 (en) Non-natural consensus albumin binding domains
CY1124050T1 (en) HUMAN CD30 ANTIGEN BINDING PROTEINS
MX2018001040A (en) Artificial nucleic acid molecules.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
MX364690B (en) Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system.
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins 21
MX357803B (en) Artificial nucleic acid molecules.
MX2016009771A (en) Methods and products for nucleic acid production and delivery.
MX2015008446A (en) Multivalent binding protein compositions.
PH12018501404A1 (en) Forms of rifaximin and uses thereof
MX346923B (en) Genes and proteins for alkanoyl-coa synthesis.
EP2670443A4 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
MX366130B (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same.
MX358706B (en) Artificial nucleic acid molecules comprising a 5'top utr.
CY1114483T1 (en) NEW REGULATORY INFORMATION
MX2014010750A (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof.
BR112014006158A2 (en) binding molecule, nucleic acid molecule, vector, host cell, process for preparing a binding molecule, methods for enhancing an immune response in a human individual, for treating cancer in a human individual in need thereof, for reducing the size of a tumor or inhibit the growth of cancer cells in an individual or reduce or inhibit the development of metastatic cancer in an individual suffering from cancer, use of a binding molecule, and pharmaceutical composition
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX364922B (en) Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1.
BR112014015016A8 (en) HOMODIMERIC PROTEIN OF TWO IDENTICAL AMINO ACID CHAINS, AMINO ACID CHAIN, NUCLEIC ACID MOLECULE, PHARMACEUTICAL COMPOSITION, HOST CELL, METHOD OF PREPARATION OF A HOMODIMERIC PROTEIN, METHOD FOR PREPARING A VACCINE, VACCINE AND METHOD OF TREATMENT OR PREVENTION
MX369550B (en) Fgfr3 fusion gene and pharmaceutical drug targeting same.

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ONCOS THERAPEUTICS LTD.

FD Application lapsed